Brokerages expect Healthequity Inc (NASDAQ:HQY) to post $0.28 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Healthequity’s earnings, with the lowest EPS estimate coming in at $0.27 and the highest estimate coming in at $0.29. Healthequity posted earnings per share of $0.27 during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.7%. The business is expected to issue its next quarterly earnings results on Tuesday, September 4th.
According to Zacks, analysts expect that Healthequity will report full year earnings of $1.05 per share for the current financial year, with EPS estimates ranging from $1.02 to $1.07. For the next fiscal year, analysts expect that the business will post earnings of $1.32 per share, with EPS estimates ranging from $1.22 to $1.43. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Healthequity.
Healthequity (NASDAQ:HQY) last released its earnings results on Monday, June 4th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.09. Healthequity had a return on equity of 13.47% and a net margin of 22.91%. The company had revenue of $69.90 million for the quarter, compared to the consensus estimate of $68.81 million. During the same quarter last year, the business posted $0.23 EPS. Healthequity’s quarterly revenue was up 26.2% compared to the same quarter last year.
A number of research analysts have commented on the company. Oppenheimer increased their target price on Healthequity from $58.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. KeyCorp increased their target price on Healthequity from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Tuesday, June 5th. Zacks Investment Research downgraded Healthequity from a “buy” rating to a “hold” rating in a report on Saturday, May 12th. SunTrust Banks increased their target price on Healthequity from $70.00 to $85.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Finally, Barrington Research increased their target price on Healthequity to $85.00 and gave the stock an “outperform” rating in a report on Tuesday, June 5th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $77.00.
In related news, VP Angelique Christine Hill sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $77.45, for a total value of $619,600.00. Following the sale, the vice president now owns 18,471 shares of the company’s stock, valued at approximately $1,430,578.95. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Ashley Dreier sold 16,250 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $67.00, for a total value of $1,088,750.00. Following the completion of the sale, the vice president now directly owns 49,439 shares in the company, valued at approximately $3,312,413. The disclosure for this sale can be found here. In the last three months, insiders sold 478,790 shares of company stock worth $33,070,800. Company insiders own 4.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Healthequity by 2.4% in the 1st quarter. BlackRock Inc. now owns 6,910,853 shares of the company’s stock valued at $418,384,000 after acquiring an additional 159,362 shares during the period. JPMorgan Chase & Co. increased its position in Healthequity by 6.8% in the 1st quarter. JPMorgan Chase & Co. now owns 1,229,111 shares of the company’s stock valued at $74,411,000 after acquiring an additional 78,021 shares during the period. Carillon Tower Advisers Inc. acquired a new stake in Healthequity in the 4th quarter valued at approximately $34,100,000. Northern Trust Corp increased its position in Healthequity by 1.5% in the 1st quarter. Northern Trust Corp now owns 664,085 shares of the company’s stock valued at $40,204,000 after acquiring an additional 9,575 shares during the period. Finally, TimesSquare Capital Management LLC increased its position in Healthequity by 33.4% in the 4th quarter. TimesSquare Capital Management LLC now owns 644,535 shares of the company’s stock valued at $30,074,000 after acquiring an additional 161,335 shares during the period. Hedge funds and other institutional investors own 96.58% of the company’s stock.
Healthequity traded up $2.84, reaching $77.05, during trading hours on Thursday, MarketBeat reports. 743,600 shares of the stock were exchanged, compared to its average volume of 612,415. Healthequity has a 52 week low of $40.21 and a 52 week high of $82.04. The company has a market cap of $4.78 billion, a PE ratio of 142.69, a P/E/G ratio of 3.21 and a beta of 1.42.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Get a free copy of the Zacks research report on Healthequity (HQY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.